Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,786
archived clinical trials in
Dermatology

Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Science Institute
mi
from
Santa Monica, CA
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Science Institute
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Danbury Clinical Research, LLC
mi
from
Danbury, CT
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Danbury Clinical Research, LLC
mi
from
Danbury, CT
Click here to add this to my saved trials
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
International Dermatology Research, Inc.
mi
from
Miami, FL
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
International Dermatology Research, Inc.
mi
from
Miami, FL
Click here to add this to my saved trials
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Medical Dermatology Specialists
mi
from
Atlanta, GA
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Medical Dermatology Specialists
mi
from
Atlanta, GA
Click here to add this to my saved trials
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
The Indiana Clinical Trials Center, PC
mi
from
Plainfield, IN
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
The Indiana Clinical Trials Center, PC
mi
from
Plainfield, IN
Click here to add this to my saved trials
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Wake Research, LLC
mi
from
Raleigh, NC
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Wake Research, LLC
mi
from
Raleigh, NC
Click here to add this to my saved trials
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Dermatologists of Greater Columbus
mi
from
Bexley, OH
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Dermatologists of Greater Columbus
mi
from
Bexley, OH
Click here to add this to my saved trials
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
National Allergy and Asthma Research, LLC
mi
from
North Charleston, SC
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
National Allergy and Asthma Research, LLC
mi
from
North Charleston, SC
Click here to add this to my saved trials
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
University Hospital Antwerp
mi
from
Antwerp,
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
University Hospital Antwerp
mi
from
Antwerp,
Click here to add this to my saved trials
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
California Dermatology and Clinical Research Institute
mi
from
Encinitas, CA
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
California Dermatology and Clinical Research Institute
mi
from
Encinitas, CA
Click here to add this to my saved trials
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
First OC Dermatology
mi
from
Fountain Valley, CA
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
First OC Dermatology
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Respiratory Medicine Research
mi
from
Ypsilanti, MI
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Respiratory Medicine Research
mi
from
Ypsilanti, MI
Click here to add this to my saved trials
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Oregon Dermatology & Research
mi
from
Portland, OR
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Oregon Dermatology & Research
mi
from
Portland, OR
Click here to add this to my saved trials
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Dermatology Research Associates
mi
from
Los Angeles, CA
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Dermatology Research Associates
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
L & C Professional Medical Research
mi
from
Miami, FL
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
L & C Professional Medical Research
mi
from
Miami, FL
Click here to add this to my saved trials
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Lenus Research & Medical Group
mi
from
Sweetwater, FL
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Lenus Research & Medical Group
mi
from
Sweetwater, FL
Click here to add this to my saved trials
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Olympian Clinical Research
mi
from
Tampa, FL
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Olympian Clinical Research
mi
from
Tampa, FL
Click here to add this to my saved trials
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Study Center
mi
from
Bangor, ME
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Study Center
mi
from
Bangor, ME
Click here to add this to my saved trials
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Mount Sinai West Dermatoogy
mi
from
New York, NY
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Mount Sinai West Dermatoogy
mi
from
New York, NY
Click here to add this to my saved trials
A Study of the Safety, Engraftment, and Action of NB01 in Adults With Moderate Acne
A Phase IB Dose Escalating Study of the Safety, Short-Term Engraftment and Action of a Singly-Applied NB01 in Adults With Moderate Acne
Status: Enrolling
Updated:  12/31/1969
Dermatology Research Associates
mi
from
Los Angeles, CA
A Study of the Safety, Engraftment, and Action of NB01 in Adults With Moderate Acne
A Phase IB Dose Escalating Study of the Safety, Short-Term Engraftment and Action of a Singly-Applied NB01 in Adults With Moderate Acne
Status: Enrolling
Updated: 12/31/1969
Dermatology Research Associates
mi
from
Los Angeles, CA
Click here to add this to my saved trials
LaseMD System for the Treatment of Melasma
Evaluation of the Lutronic LaseMD System for the Treatment of Melasma
Status: Enrolling
Updated:  12/31/1969
Laser and Skin Surgery Center of New York
mi
from
New York, NY
LaseMD System for the Treatment of Melasma
Evaluation of the Lutronic LaseMD System for the Treatment of Melasma
Status: Enrolling
Updated: 12/31/1969
Laser and Skin Surgery Center of New York
mi
from
New York, NY
Click here to add this to my saved trials
A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo
An Open-Label Pilot Study of the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered Twice-Daily in Adult Subjects With Non-Segmental Facial Vitiligo
Status: Enrolling
Updated:  12/31/1969
Aclaris Investigational Site
mi
from
Encinitas, CA
A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo
An Open-Label Pilot Study of the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered Twice-Daily in Adult Subjects With Non-Segmental Facial Vitiligo
Status: Enrolling
Updated: 12/31/1969
Aclaris Investigational Site
mi
from
Encinitas, CA
Click here to add this to my saved trials
A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo
An Open-Label Pilot Study of the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered Twice-Daily in Adult Subjects With Non-Segmental Facial Vitiligo
Status: Enrolling
Updated:  12/31/1969
Aclaris Investigational Site
mi
from
Los Angeles, CA
A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo
An Open-Label Pilot Study of the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered Twice-Daily in Adult Subjects With Non-Segmental Facial Vitiligo
Status: Enrolling
Updated: 12/31/1969
Aclaris Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo
An Open-Label Pilot Study of the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered Twice-Daily in Adult Subjects With Non-Segmental Facial Vitiligo
Status: Enrolling
Updated:  12/31/1969
Aclaris Investigator Site
mi
from
Worcester, MA
A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo
An Open-Label Pilot Study of the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered Twice-Daily in Adult Subjects With Non-Segmental Facial Vitiligo
Status: Enrolling
Updated: 12/31/1969
Aclaris Investigator Site
mi
from
Worcester, MA
Click here to add this to my saved trials
A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo
An Open-Label Pilot Study of the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered Twice-Daily in Adult Subjects With Non-Segmental Facial Vitiligo
Status: Enrolling
Updated:  12/31/1969
Aclaris Investigator Site
mi
from
Dallas, TX
A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo
An Open-Label Pilot Study of the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered Twice-Daily in Adult Subjects With Non-Segmental Facial Vitiligo
Status: Enrolling
Updated: 12/31/1969
Aclaris Investigator Site
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo
An Open-Label Pilot Study of the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered Twice-Daily in Adult Subjects With Non-Segmental Facial Vitiligo
Status: Enrolling
Updated:  12/31/1969
Aclaris Investigational Site
mi
from
Lynchburg, VA
A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo
An Open-Label Pilot Study of the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered Twice-Daily in Adult Subjects With Non-Segmental Facial Vitiligo
Status: Enrolling
Updated: 12/31/1969
Aclaris Investigational Site
mi
from
Lynchburg, VA
Click here to add this to my saved trials
A 4-Day Study to Evaluate Phototoxicity of CCP-020 (Diacerein 1%) in Healthy Subjects
A 4 Day, Randomized Study to Evaluate the Potential of CCP-020 (Diacerein 1%) Topical Ointment to Induce a Phototoxicity Skin Reaction in Healthy Subjects, Using a Controlled Photopatch Test
Status: Enrolling
Updated:  12/31/1969
TKL research
mi
from
Fair Lawn, NJ
A 4-Day Study to Evaluate Phototoxicity of CCP-020 (Diacerein 1%) in Healthy Subjects
A 4 Day, Randomized Study to Evaluate the Potential of CCP-020 (Diacerein 1%) Topical Ointment to Induce a Phototoxicity Skin Reaction in Healthy Subjects, Using a Controlled Photopatch Test
Status: Enrolling
Updated: 12/31/1969
TKL research
mi
from
Fair Lawn, NJ
Click here to add this to my saved trials
Prospective Single Center Randomized Double Blind Controlled Tolerability Trial of Six Hair Cleansing Conditioners
Prospective Single Center Randomized Double Blind Controlled Tolerability Trial of Six Hair Cleansing Conditioners
Status: Enrolling
Updated:  12/31/1969
Park Nicollet Contact Dermatitis Clinic
mi
from
Minneapolis, MN
Prospective Single Center Randomized Double Blind Controlled Tolerability Trial of Six Hair Cleansing Conditioners
Prospective Single Center Randomized Double Blind Controlled Tolerability Trial of Six Hair Cleansing Conditioners
Status: Enrolling
Updated: 12/31/1969
Park Nicollet Contact Dermatitis Clinic
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Sculptra Aesthetic for the Treatment of Upper Knee Skin Laxity
A Randomized, Split-body Clinical Trial of Poly-L-lactic Acid (Sculptra Aesthetic) for the Treatment of Upper Knee Skin Laxity
Status: Enrolling
Updated:  12/31/1969
West Dermatology Research Center
mi
from
San Diego, CA
Sculptra Aesthetic for the Treatment of Upper Knee Skin Laxity
A Randomized, Split-body Clinical Trial of Poly-L-lactic Acid (Sculptra Aesthetic) for the Treatment of Upper Knee Skin Laxity
Status: Enrolling
Updated: 12/31/1969
West Dermatology Research Center
mi
from
San Diego, CA
Click here to add this to my saved trials
Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Determine Efficacy and Safety of IFX-1 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  12/31/1969
InflaRx Investigational Site
mi
from
Saint Joseph, MO
Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Determine Efficacy and Safety of IFX-1 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 12/31/1969
InflaRx Investigational Site
mi
from
Saint Joseph, MO
Click here to add this to my saved trials
Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Determine Efficacy and Safety of IFX-1 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  12/31/1969
InflaRx Investigational Site
mi
from
Goodlettsville, TN
Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Determine Efficacy and Safety of IFX-1 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 12/31/1969
InflaRx Investigational Site
mi
from
Goodlettsville, TN
Click here to add this to my saved trials
Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Determine Efficacy and Safety of IFX-1 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  12/31/1969
InflaRX Investigational Site
mi
from
Fort Myers, FL
Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Determine Efficacy and Safety of IFX-1 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 12/31/1969
InflaRX Investigational Site
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Determine Efficacy and Safety of IFX-1 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  12/31/1969
InflaRX Investigational Site
mi
from
Sandy Springs, GA
Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Determine Efficacy and Safety of IFX-1 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 12/31/1969
InflaRX Investigational Site
mi
from
Sandy Springs, GA
Click here to add this to my saved trials
Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Determine Efficacy and Safety of IFX-1 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  12/31/1969
InflaRX Investigational Site
mi
from
Sofia,
Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Determine Efficacy and Safety of IFX-1 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 12/31/1969
InflaRX Investigational Site
mi
from
Sofia,
Click here to add this to my saved trials
Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Determine Efficacy and Safety of IFX-1 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  12/31/1969
InflaRX Investigational Site
mi
from
Dearborn, MI
Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Determine Efficacy and Safety of IFX-1 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 12/31/1969
InflaRX Investigational Site
mi
from
Dearborn, MI
Click here to add this to my saved trials
Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Determine Efficacy and Safety of IFX-1 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  12/31/1969
InflaRX Investigational Site
mi
from
Columbia, MO
Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Determine Efficacy and Safety of IFX-1 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 12/31/1969
InflaRX Investigational Site
mi
from
Columbia, MO
Click here to add this to my saved trials
Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Determine Efficacy and Safety of IFX-1 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  12/31/1969
InflaRX Investigational Site
mi
from
Saint Louis, MO
Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Determine Efficacy and Safety of IFX-1 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 12/31/1969
InflaRX Investigational Site
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Determine Efficacy and Safety of IFX-1 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  12/31/1969
InflaRX Investigational Site
mi
from
Chapel Hill, NC
Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Determine Efficacy and Safety of IFX-1 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 12/31/1969
InflaRX Investigational Site
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Determine Efficacy and Safety of IFX-1 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  12/31/1969
InflaRX Investigational Site
mi
from
Birmingham, AL
Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Determine Efficacy and Safety of IFX-1 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 12/31/1969
InflaRX Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Determine Efficacy and Safety of IFX-1 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  12/31/1969
InflaRX Investigational Site
mi
from
Miami, FL
Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Determine Efficacy and Safety of IFX-1 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 12/31/1969
InflaRX Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Determine Efficacy and Safety of IFX-1 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  12/31/1969
InflaRX Investigational Site
mi
from
Cincinnati, OH
Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Determine Efficacy and Safety of IFX-1 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 12/31/1969
InflaRX Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Determine Efficacy and Safety of IFX-1 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  12/31/1969
InflaRX Investigational Site
mi
from
Hershey, PA
Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Determine Efficacy and Safety of IFX-1 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 12/31/1969
InflaRX Investigational Site
mi
from
Hershey, PA
Click here to add this to my saved trials
An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses
An Open-Label Study Assessing Subject Satisfaction With A-101 Hydrogen Peroxide Topical Solution, 40% (w/w) Treatment for Seborrheic Keratoses of the Face, Neck, and Decolletage
Status: Enrolling
Updated:  12/31/1969
Aclaris Investigational Site
mi
from
Fort Washington, PA
An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses
An Open-Label Study Assessing Subject Satisfaction With A-101 Hydrogen Peroxide Topical Solution, 40% (w/w) Treatment for Seborrheic Keratoses of the Face, Neck, and Decolletage
Status: Enrolling
Updated: 12/31/1969
Aclaris Investigational Site
mi
from
Fort Washington, PA
Click here to add this to my saved trials
An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses
An Open-Label Study Assessing Subject Satisfaction With A-101 Hydrogen Peroxide Topical Solution, 40% (w/w) Treatment for Seborrheic Keratoses of the Face, Neck, and Decolletage
Status: Enrolling
Updated:  12/31/1969
Aclaris Investigational Site
mi
from
Knoxville, TN
An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses
An Open-Label Study Assessing Subject Satisfaction With A-101 Hydrogen Peroxide Topical Solution, 40% (w/w) Treatment for Seborrheic Keratoses of the Face, Neck, and Decolletage
Status: Enrolling
Updated: 12/31/1969
Aclaris Investigational Site
mi
from
Knoxville, TN
Click here to add this to my saved trials
An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses
An Open-Label Study Assessing Subject Satisfaction With A-101 Hydrogen Peroxide Topical Solution, 40% (w/w) Treatment for Seborrheic Keratoses of the Face, Neck, and Decolletage
Status: Enrolling
Updated:  12/31/1969
Aclaris Investigational Site
mi
from
Austin, TX
An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses
An Open-Label Study Assessing Subject Satisfaction With A-101 Hydrogen Peroxide Topical Solution, 40% (w/w) Treatment for Seborrheic Keratoses of the Face, Neck, and Decolletage
Status: Enrolling
Updated: 12/31/1969
Aclaris Investigational Site
mi
from
Austin, TX
Click here to add this to my saved trials
Platelet Rich Plasma Versus Minoxidil Foam for Treatment of Androgenic Alopecia in Women
A Randomized Controlled Trial Comparing Platelet Rich Plasma (PRP) to Minoxidil Foam for Treatment of Androgenic Alopecia in Women
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Florida
mi
from
Jacksonville, FL
Platelet Rich Plasma Versus Minoxidil Foam for Treatment of Androgenic Alopecia in Women
A Randomized Controlled Trial Comparing Platelet Rich Plasma (PRP) to Minoxidil Foam for Treatment of Androgenic Alopecia in Women
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Florida
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Project Options - The ABC Method
Efficacy of a Behavioral Intervention to Reduce Skin Cancer Risk Among Patients
Status: Enrolling
Updated:  12/31/1969
Penn State Health Milton S. Hershey Medical Center
mi
from
Hershey, PA
Project Options - The ABC Method
Efficacy of a Behavioral Intervention to Reduce Skin Cancer Risk Among Patients
Status: Enrolling
Updated: 12/31/1969
Penn State Health Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution
An Open-Label Safety, Tolerability, and Efficacy Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution
Status: Enrolling
Updated:  12/31/1969
Aclaris Investigational Site
mi
from
Denver, CO
A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution
An Open-Label Safety, Tolerability, and Efficacy Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution
Status: Enrolling
Updated: 12/31/1969
Aclaris Investigational Site
mi
from
Denver, CO
Click here to add this to my saved trials
A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution
An Open-Label Safety, Tolerability, and Efficacy Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution
Status: Enrolling
Updated:  12/31/1969
Aclaris Investigator Site
mi
from
Portland, OR
A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution
An Open-Label Safety, Tolerability, and Efficacy Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution
Status: Enrolling
Updated: 12/31/1969
Aclaris Investigator Site
mi
from
Portland, OR
Click here to add this to my saved trials